

Tetsuro Kikuchi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9619318/publications.pdf>

Version: 2024-02-01

12
papers

1,655
citations

840119

11
h-index

1281420

11
g-index

13
all docs

13
docs citations

13
times ranked

1389
citing authors

#	ARTICLE	IF	CITATIONS
1	Aripiprazole, a Novel Antipsychotic, Is a High-Affinity Partial Agonist at Human Dopamine D2 Receptors. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 302, 381-389.	1.3	856
2	Brexipiprazole I: In Vitro and In Vivo Characterization of a Novel Serotonin-Dopamine Activity Modulator. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 350, 589-604.	1.3	284
3	Novel Antipsychotic Agents with Dopamine Autoreceptor Agonist Properties: Synthesis and Pharmacology of 7-[4-(4-Phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone Derivatives. <i>Journal of Medicinal Chemistry</i> , 1998, 41, 658-667.	2.9	145
4	Brexipiprazole II: Antipsychotic-Like and Procognitive Effects of a Novel Serotonin-Dopamine Activity Modulator. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 350, 605-614.	1.3	112
5	Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic. <i>European Journal of Pharmacology</i> , 2005, 515, 10-19.	1.7	79
6	The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release. <i>Brain Research</i> , 2004, 1003, 9-17.	1.1	55
7	Effects of brexipiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: A role for serotonin 5-HT1A receptors. <i>Pharmacology Biochemistry and Behavior</i> , 2014, 124, 245-249.	1.3	38
8	Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. <i>European Journal of Pharmacology</i> , 2009, 607, 35-40.	1.7	31
9	Discovery research and development history of the dopamine D ₂ receptor partial agonists, aripiprazole and brexipiprazole. <i>Neuropsychopharmacology Reports</i> , 2021, 41, 134-143.	1.1	23
10	Brexipiprazole has a low risk of dopamine D ₂ receptor sensitization and inhibits rebound phenomena related to D ₂ and serotonin 5-HT _{2A} receptors in rats. <i>Neuropsychopharmacology Reports</i> , 2019, 39, 279-288.	1.1	19
11	Is Memantine Effective as an NMDA Receptor Antagonist in Adjunctive Therapy for Schizophrenia?. <i>Biomolecules</i> , 2020, 10, 1134.	1.8	13
12	The Dopamine D2 Receptor Partial Agonist Antipsychotics, Aripiprazole, and Brexipiprazole. , 2021, , 1-45.		0